Novartis is reimagining cancer care with radioligand therapies (RLTs) for patients with advanced cancers, including neuroendocrine tumors. We are proud of our 30-year legacy as an innovator in the neuroendocrine tumor community, leading developments that strive to transform the lives of people with this rare disease.
At Novartis, we have a commitment to working together with patients. Our significant investment in research and development underpins our commitment to using science-based innovation to address some of society's most challenging healthcare issues. Only by working together can we improve outcomes for patients and change the practice of medicine.
For more information, please visit: https://us.lutathera.com.
Submit Your Question to Novartis
2025 ANNUAL PATIENT CONFERENCE
This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by NCF. Talk to your medical team about your individual care and treatment.